Last reviewed · How we verify
NCT05886933
Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet
trial testing Fexuprazan Hydrochloride in Gastroesophageal Reflux Disease in 9,846 participants. Completed in 31 December 2024.
30 April 2024
Quick facts
| Lead sponsor | Daewoong Pharmaceutical Co. LTD. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 9,846 |
| Start date | 22 May 2023 |
| Primary completion | 30 April 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Fexuprazan Hydrochloride — full drug profile →
Conditions studied
- Gastroesophageal Reflux Disease — all drugs for Gastroesophageal Reflux Disease →
Sponsor
Daewoong Pharmaceutical Co. LTD. — full company profile →
Who can join
Adults 19 to 75, any sex, with Gastroesophageal Reflux Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This observational study is a large-scale, prospective, and multi-institutional observational study. Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration of Pexuclue tablet.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05886933
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fexuprazan Hydrochloride
Trials testing the same drug.
- NCT05946135 — Efficacy of Fexuprazan for Prevention or Control of Gastritis Symptoms in Patients on Treatment With Systemic Steroids · Phase 4 · completed
- NCT05660122 — A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab · completed
Other recruiting trials for Gastroesophageal Reflux Disease
Currently open trials in the same condition.
- NCT06783751 — Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG) · NA · recruiting
- NCT06348420 — Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment · NA · recruiting
- NCT06991348 — Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Dise · Phase 4 · recruiting
- NCT06732661 — Preserving the Pre-cardial Fat Pad During Sleeve Gastrectomy on Postoperative Gastroesophageal Reflux · NA · active not recruiting
- NCT05514769 — Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer · NA · recruiting
Other Daewoong Pharmaceutical Co. LTD. trials
Trials by the same sponsor.
- NCT07515560 — Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study · not yet recruiting
- NCT07516977 — Noseguard for Prevention of Respiratory Infections in Real-World Use · NA · not yet recruiting
- NCT07539415 — A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Hea · Phase 1 · not yet recruiting
- NCT07267221 — Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers · Phase 1 · recruiting
- NCT07256600 — PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05886933 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Daewoong Pharmaceutical Co. LTD.
- Last refreshed: 24 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05886933.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing